Darglitazone NEW
| Price | $32 | $53 | $88 |
| Package | 2mg | 5mg | 10mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Darglitazone | CAS No.: 141200-24-0 |
| Purity: 99.19% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Darglitazone |
| Description | Darglitazone (CP-86325) is a potent, selective agonist of PPAR-γ with antidiabetic actions. Darglitazone is effective in controlling blood glucose and lipid metabolism. |
| In vitro | Darglitazone (30 μM) stimulated UCP2 gene expression, likely through PPAR-γ, and increased UCP2 mRNA levels in cell lines representing white (3T3-L1 and 3T3-F442A), brown (HIB-1B) adipose tissues, and skeletal muscle (L6) [1]. |
| In vivo | In male diabetic ob/ob mice, Darglitazone dramatically reduces the infarct size in the ob/ob mice at 24?h of recovery. Normalized blood glucose and reduced circulating triglycerides (TG) and very-low-density lipoproteins (VLDL) in diabetic ob/ob mice without having any effect in the nondiabetic mice. Darglitazone treatment restores acute cerebral inflammatory responses that were absent in the diabetic mice and profoundly improved their recovery from hypoxic-ischemic (H/I) insult[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (130.8 mM) Ethanol : ≤ 5 mg/mL |
| Keywords | oral | UCP2 | corticosterone | PPAR-γ | Diabetes | CP86325 | Inhibitor | PPAR | inhibit | Darglitazone | Peroxisome proliferator-activated receptors | thiazolidinedione | CP 86325 |
| Inhibitors Related | PHYTOL | Daidzein | Gemfibrozil | Fenofibrate | Pioglitazone hydrochloride | 5-Aminosalicylic Acid | Naringenin | Fisetin | 2,3-Butanediol | Icariin |
| Related Compound Libraries | Nuclear Receptor Compound Library | DNA Damage & Repair Compound Library | Anti-Pancreatic Cancer Compound Library | Bioactive Compound Library | Anti-Breast Cancer Compound Library | Orally Active Compound Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Human Metabolite Library | Transcription Factor-Targeted Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $3520.00/100mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY